Diagenode

C/EBPα Activates Pre-existing and De Novo Macrophage Enhancers during Induced Pre-B Cell Transdifferentiation and Myelopoiesis


van Oevelen C, Collombet S, Vicent G, Hoogenkamp M, Lepoivre C, Badeaux A, Bussmann L, Sardina JL, Thieffry D, Beato M, Shi Y, Bonifer C, Graf T

Highlights

  • C/EBPα activates two classes of prospective myeloid enhancers in B cells
  • Pre-existing enhancers are bound by PU.1 and become hyper-activated by C/EBPα
  • C/EBPα acts as a pioneer factor with delayed kinetics on de novo enhancers
  • The two types of enhancers direct myeloid cell fate in B cells and hematopoiesis

Summary

Transcription-factor-induced somatic cell conversions are highly relevant for both basic and clinical research yet their mechanism is not fully understood and it is unclear whether they reflect normal differentiation processes. Here we show that during pre-B-cell-to-macrophage transdifferentiation, C/EBPα binds to two types of myeloid enhancers in B cells: pre-existing enhancers that are bound by PU.1, providing a platform for incoming C/EBPα; and de novo enhancers that are targeted by C/EBPα, acting as a pioneer factor for subsequent binding by PU.1. The order of factor binding dictates the upregulation kinetics of nearby genes. Pre-existing enhancers are broadly active throughout the hematopoietic lineage tree, including B cells. In contrast, de novo enhancers are silent in most cell types except in myeloid cells where they become activated by C/EBP factors. Our data suggest that C/EBPα recapitulates physiological developmental processes by short-circuiting two macrophage enhancer pathways in pre-B cells.

Tags
Antibody

Share this article

Published
August, 2015

Source

Related product

  • Histone-Deacetylase-polyclonal-antibody-diagenode
    C15410037-50
    H3K4me1 polyclonal antibody - Classic

Events

 See all events

Twitter feed

News

 See all news